Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Endocrine 15NET 4Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 208Carcinoid Tumor 26Neoplasms 22Pancreatic Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 14Carcinoma, Neuroendocrine 11Carcinoma 11Adenoma, Islet Cell 11Neoplasm Metastasis 10Colorectal Neoplasms 9Lung Neoplasms 8Serotonin Syndrome 7Prostatic Neoplasms 7Adenocarcinoma 7Pheochromocytoma 6Gastrointestinal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Somatostatinoma 5Neuroblastoma 5Melanoma 5Gastroenteropancreatic Neuroendocrine Tumors 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Vipoma 4Sarcoma 4Rectal Neoplasms 4Paraganglioma 4

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Acromegaly × NET × Clear all
NCT06253897 2024-12-24

BackSOM

Ipsen

Completed
20 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01840449 2019-01-14

SOPRANo

Ipsen

Completed
156 enrolled
EndocrineNET

Acromegaly, Neuroendocrine Tumors

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Camurus AB

Phase 2 Completed
12 enrolled 18 charts
EndocrineNET

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡